Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia [Short Communication]

• Published in: The international journal of tuberculosis and lung disease Vol. 11; no. 5; pp. 585 - 587
• Main Authors: RIEKSTINA, V, LEIMANE, V, HOLTZ, T. H, LEIMANS, J, WELLS, C. D
• Format: Journal Article
• Language: English
• Published: Paris, France IUATLD 01-05-2007; Union internationale contre la tuberculose et les maladies respiratoires
• Subjects: Antitubercular Agents - administration & dosage; Biological and medical sciences; Cohort Analysis; Cohort Studies; Directly Observed Therapy - methods; Humans; Latvia; Medical sciences; Miscellaneous; Multidrug-Resistant Tuberculosis; Pneumology; Prevention and actions; Program Evaluation; Public health. Hygiene; Public health. Hygiene-occupational medicine; Treatment Outcome; Treatment Outcomes; Tuberculosis; Tuberculosis - drug therapy; Tuberculosis - mortality; Tuberculosis, Multidrug-Resistant - drug therapy; Tuberculosis, Multidrug-Resistant - mortality; Eastern Europe; Latvia; Europe; Prognosis; cohort analysis; Mycobacterial infection; Drug compliance; treatment outcomes; Cohort study; Multiple resistance; Bacteria; Evolution; Treatment compliance; Antituberculous agent; Public health; Human; Sanitary program; Drug combination; Treatment resistance; multidrug-resistant tuberculosis; Infection; Chemotherapy; Treatment; Tuberculosis; Mycobacterium tuberculosis; Mycobacteriales; Bacteriosis; Mycobacteriaceae; Actinomycetes; Antibacterial agent
• ISSN: 1027-3719; 1815-7920

International guidelines for treatment outcome analysis of tuberculosis cases have been published and are widely used. They do not, however, fully address the incorporation of multidrug-resistant tuberculosis (MDR-TB) cases. Here we present an approach to cohort analysis of treatment
outcomes for all registered TB cases, including MDR-TB cases. We analyzed all new pulmonary smear- and/or culture-positive cases registered in Latvia during 2002. Analysis of treatment outcomes at 24 months after initial case registration showed overall treatment success at 84%. This approach
to outcome analysis is possible only for settings where MDR-TB treatment is established.